PriceTargets.com logo

Quipt Home Medical - QIPT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.25
  • Forecasted Upside: 91.29%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 2 Strong Buy Ratings
$3.79 As of 07/26/2024 01:00 AM ET
▲ +0.03 (0.80%)

This chart shows the closing price for QIPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Quipt Home Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QIPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QIPT

Analyst Price Target is $7.25
▲ +91.29% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Quipt Home Medical in the last 3 months. The average price target is $7.25, with a high forecast of $9.50 and a low forecast of $2.50. The average price target represents a 91.29% upside from the last price of $3.79.

This chart shows the closing price for QIPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Quipt Home Medical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2023
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/3/2023
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/1/2023
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/30/2023
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/28/2024
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/27/2024
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/26/2024
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
7/26/2024

Latest Recommendations

  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/16/2024Ventum Cap MktsUpgradeStrong-BuyLow
5/20/2024BenchmarkLower TargetBuy ➝ Buy$10.00 ➝ $9.00Low
5/17/2024Eight CapitalUpgradeStrong-BuyLow
5/17/2024Stifel NicolausLower TargetBuy$10.50 ➝ $9.50Low
5/17/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$9.00 ➝ $8.00Low
5/17/2024Raymond JamesDowngradeMarket Perform ➝ Underperform$10.00 ➝ $2.50Low
2/16/2024Raymond JamesDowngradeOutperform ➝ Market Perform$10.00Low
12/20/2023BenchmarkReiterated RatingBuy ➝ Buy$10.00Low
8/17/2023Raymond JamesLower TargetOutperform$11.00 ➝ $10.00Low
2/13/2023BenchmarkReiterated RatingBuy$10.00Low
1/4/2023Raymond JamesBoost TargetOutperform$10.00 ➝ $14.00Low
10/24/2022Canaccord Genuity GroupBoost TargetC$11.00 ➝ C$11.25Low
8/18/2022Canaccord Genuity GroupLower TargetBuy ➝ BuyC$11.25 ➝ C$11.00Low
8/17/2022Raymond JamesBoost TargetOutperform$9.00 ➝ $10.00Low
4/28/2022Raymond JamesSet TargetOutperform$9.00High
2/16/2022Raymond JamesReiterated RatingOutperform$11.50Medium
1/31/2022Raymond JamesSet TargetOutperform$9.00Low
12/17/2021Raymond JamesSet TargetOutperform$9.00Medium
11/24/2021Raymond JamesSet TargetOutperform$9.00Low
11/17/2021Raymond JamesSet TargetOutperform$9.00Low
11/17/2021Stifel NicolausBoost TargetBuyC$12.40 ➝ C$12.75Low
11/9/2021Echelon Wealth PartnersReiterated RatingBuyMedium
10/20/2021BenchmarkInitiated CoverageBuy$7.50High
8/25/2021Raymond JamesReiterated RatingOutperform$9.00Low
7/15/2021Raymond JamesLower TargetOutperform$11.25 ➝ $10.00High
6/2/2021Leede Jones GabReiterated RatingBuyLow
6/2/2021Colliers SecuritiesReiterated RatingBuyLow
6/1/2021Beacon SecuritiesReiterated RatingBuyLow
(Data available from 7/26/2019 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/26/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/26/2024

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Quipt Home Medical logo
Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.
Read More

Today's Range

Now: $3.79
Low: $3.66
High: $3.79

50 Day Range

MA: $3.26
Low: $2.95
High: $3.79

52 Week Range

Now: $3.79
Low: $2.85
High: $6.01

Volume

241,971 shs

Average Volume

187,081 shs

Market Capitalization

$161.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Quipt Home Medical?

The following equities research analysts have issued research reports on Quipt Home Medical in the last year: Benchmark Co., Canaccord Genuity Group Inc., Eight Capital, Raymond James, Stifel Nicolaus, and Ventum Cap Mkts.
View the latest analyst ratings for QIPT.

What is the current price target for Quipt Home Medical?

4 Wall Street analysts have set twelve-month price targets for Quipt Home Medical in the last year. Their average twelve-month price target is $7.25, suggesting a possible upside of 91.3%. Stifel Nicolaus has the highest price target set, predicting QIPT will reach $9.50 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $2.50 for Quipt Home Medical in the next year.
View the latest price targets for QIPT.

What is the current consensus analyst rating for Quipt Home Medical?

Quipt Home Medical currently has 1 sell rating, 3 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe QIPT will outperform the market and that investors should add to their positions of Quipt Home Medical.
View the latest ratings for QIPT.

What other companies compete with Quipt Home Medical?

Other companies that are similar to Quipt Home Medical include Castle Biosciences, Grail, DocGo, LifeMD and AirSculpt Technologies. Learn More about companies similar to Quipt Home Medical.

How do I contact Quipt Home Medical's investor relations team?

The company's listed phone number is 859-878-2220 and its investor relations email address is [email protected]. The official website for Quipt Home Medical is www.protechhomemedical.com. Learn More about contacing Quipt Home Medical investor relations.